Off-The-Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

• Type: Article in International Scientific Journal
• Date: 2025

Authors

Moura, LIF (Author) Other; Malfanti, A (Author) Other; Matos, A (Author) Other; Peres, C (Author) Other; Armiñán, A (Author) Other; Duro-Castaño, A (Author) Other; Conejos-Sánchez, I (Author) Other; Medel, M (Author) Other; Dordevic, S (Author) Other; Carrascosa, P (Author) Other; Carreira, B (Author) Other; Acúrcio, RC (Author) Other; Xavier-Ferreira, H (Author) Other; Hernández-Barranco, A (Author) Other; Castellano, E (Author) Other; Roselló, E (Author) Other; Machado JC (Author) FMUP; Peinado, H (Author) Other; Vicent, MJ (Author) Other; Florindo, HF (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: Advanced Materials

Vol. 37

ISSN: 0935-9648

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-018-0YT

DOI: 10.1002/adma.202417348

Abstract (EN): Tumor-associated antigen-based cancer vaccines suffer from limited clinical success compared to alternative immunotherapies in melanoma, an aggressive skin cancer with an immunosuppressive tumor microenvironment. The anti-tumor potential of a multivalent nanoconjugate cancer vaccine platform - a cross-linked star-shaped polyglutamate carrier (StCl) with marked lymphotropic character conjugated with melanoma-associated peptide antigens is evaluated through redox-responsive linkers. The co-delivery of melanoma-associated peptide antigens by the nanoconjugate platform induced significant effector immune responses in a mouse melanoma model. The nanoconjugate platform synergized with a PD-1 inhibitor to revert the immunosuppressive melanoma tumor microenvironment by improving cytotoxic T-cell infiltration, which prompted a superior anti-tumor effect with prolonged overall survival without acute organ toxicity. The antigen-specific anti-tumor immune response induced by the nanoconjugate platform is also validated in a melanoma patient-derived xenograft mouse model. A promising, versatile StCl-based platform is reported for generating off-the-shelf multivalent nanoconjugate cancer vaccines for the safe and efficient immunotherapeutic treatment of melanoma.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 20